NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
NEUROCRINE BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$136.98+1.27 (+0.94%)
Close on Oct 19, 2026
- Market cap
- $14.27B
- P/E (TTM)
- 20.1
- Dividend yield
- –
Share price
−$3.11 (−2.22%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
NEUROCRINE BIOSCIENCES INC grew revenue 34.4% to $3.37B over the twelve months to Jun 30, 2026. Operating income rose 60.6% to $794.80M, moving the operating margin from 19.7% to 23.6%. Free cash flow was $870.40M, up 64.6% from a year earlier.
Revenue
$3.37B
+34.4% vs. a year earlier
Operating income
$794.80M
+60.6% vs. a year earlier
Free cash flow
$870.40M
+64.6% vs. a year earlier
EPS, diluted
$6.82
+101.8% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $14.27B
- P/E ratio
- 20.1
- Price to sales
- 4.23
- Price to book
- 3.86
- Dividend yield
- –
- Free cash flow yield
- 6.10%
Fundamentals
- Revenue
- $3.37B
- Net income
- $705.50M
- EPS, diluted
- $6.82
- Free cash flow
- $870.40M
- Book value per share
- $35.45
- Diluted shares
- 104M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$3.37B+34.4% YoY
Gross profit
$3.31B+33.7% YoY
Operating income
$794.80M+60.6% YoY
Net income
$705.50M+102.6% YoY
EPS, diluted
$6.82+101.8% YoY
Free cash flow
$870.40M+64.6% YoY
Reported periodTrailing twelve months